Employer-sponsored health insurance has risen far faster than the general cost of living over the last decade. Average annual family premiums increased 47% between 2013 and 2023, according to the KFF 2023 Employer Health Benefits Survey1. Over roughly the same period, consumer prices rose about 26%, according to the U.S. Bureau of Labor Statistics Consumer Price Index2.
Budgets are stretched, benefit designs are thinning, and frustration is growing among employers and employees as more compensation is consumed by health coverage rather than take-home pay or new investment.
| Year | Average Family Premium (USD) | Cumulative Increase | U.S. Inflation (CPI) | Cumulative Increase |
| 2013 | $16,351.00 | - | 100 | - |
| 2015 | $17,545.00 | 7.00% | 103 | 3.00% |
| 2017 | $18,764.00 | 15.00% | 106 | 6.00% |
| 2019 | $20,576.00 | 26.00% | 109 | 9.00% |
| 2021 | $22,221.00 | 36.00% | 112 | 12.00% |
| 2023 | $24,225.00 | 47.00% | 126 | 26.00% |
Employers absorb most of the increase in healthcare costs to stay competitive in the labor market.
Average per-employee cost for employer-sponsored health insurance reached $16,501 in 2024, with employers expecting further increases in 2025, according to Mercer’s National Survey of Employer-Sponsored Health Plans3.
Over just the last five years, the average premium for family coverage has increased 22% compared with a 27% increase in workers’ wages and 21% inflation, according to the KFF Employer Health Benefits Survey1.
As healthcare takes a larger share of total compensation, fewer dollars remain for raises, hiring, and new initiatives, effectively acting as a quiet tax on wages and growth.
Several structural forces keep healthcare inflation persistently higher than general inflation.
Hospital and provider consolidation has increased pricing power for large health systems, allowing them to negotiate higher commercial rates without consistent gains in quality or outcomes, according to the KFF issue brief on consolidation in health care provider markets6.
Specialty drugs, used by a small share of patients with complex conditions, now account for at least half of total pharmaceutical spending in recent years, according to CarelonRx’s analysis of specialty drug growth8.
Specialty drug spending continues to grow at high single- to low double-digit rates annually, with one recent report showing a 9.6% specialty drug trend in 2024 after a 14.4% increase in 2023, according to PSG’s specialty drug trend analysis9.
Chronic diseases such as heart disease, diabetes, and cancer are the leading drivers of U.S. health spending and affect more than half of the population, with roughly 6 in 10 Americans living with at least one chronic condition, according to the National Institute for Health Care Management Foundation10 and the CDC’s chronic disease fast facts7.
Because many of these conditions are long-term and preventable, they generate recurring claims that climb over time if not managed effectively.
Beyond medical claims, employers pay substantial administrative, broker, and network access fees that add a meaningful layer of cost to total premiums, as highlighted in the Business Group on Health 2024 Large Employer Health Care Strategy Survey4.
These costs are often bundled into carrier charges, making them less visible but still material for budgeting and strategy.
Healthcare costs ratchet upward even when general inflation cools, because renewals are priced off prior claims experience and contractual rate increases.
In 2023, average annual premiums for employer-sponsored family coverage increased 7%, while inflation rose 5.8% and wages 5.2%, according to the KFF Employer Health Benefits Survey1.
Once higher costs are embedded in rates, they rarely move down, creating a long-term gap between healthcare inflation and the broader economy.
Most organizations rely on a mix of defensive and strategic responses to manage rising costs while staying competitive on benefits.
Healthcare inflation is widely expected to continue outpacing general inflation over the next several years, driven by deferred care, specialty and biologic drug utilization, and the need for competitive benefits.
The 2025 Global Medical Trends Survey projects a global average medical cost increase of 10.4% in 2025, marking the third consecutive year of double-digit growth, with North America’s medical costs expected to rise by 8.7%, according to WTW’s 2025 Global Medical Trends Survey5.
At the same time, employers anticipate continued pressure from high-cost therapies such as GLP-1 medications and gene and cell therapies, as highlighted in recent research from Mercer’s 2024 survey of employer health plans3.
A decade of runaway healthcare costs is not inevitable.
The current system often rewards volume over value and complexity over transparency, but employers now have tools to realign incentives and reset the cost curve.
By moving from passively absorbing medical trend to actively shaping a prevention-focused, data-driven healthcare strategy, employers can begin to bend their own cost curve while improving the experience and outcomes for employees and their families.